Rod Mackenzie to lead growth and innovation at Lucid Group
- Rod Mackenzie appointed as Board Chair of Lucid Group.
- Former Pfizer R&D leader to drive innovation.
- Focus on global growth strategies.
Lucid Group has announced the appointment of Rod Mackenzie, CMG, PhD, as the new Board Chair. Mackenzie, who previously led R&D at Pfizer, brings extensive experience in the pharmaceutical industry that Lucid Group aims to leverage. His leadership is expected to guide the company through its next phase of growth and innovation.
With a robust background in drug development and a proven track record at Pfizer, Mackenzie's role will focus on driving Lucid Group's global growth strategy. His experience positions him well to enhance the company’s approach to innovation, particularly in addressing the evolving needs of the health sector.
Mackenzie’s appointment emphasizes Lucid Group's commitment to advancing its mission and expanding its impact in the industry. His strategic vision is anticipated to contribute significantly to the company's objectives as it navigates future challenges and opportunities.
